Victoza Doses for Weight Loss: Titration, Timing, and What to Know

Victoza (liraglutide, a GLP-1 receptor agonist made by Novo Nordisk) is FDA-approved for type 2 diabetes, not weight loss, but clinicians sometimes prescribe it off-label for weight management. The FDA label starts Victoza at 0.6 mg once daily for one week, then 1.2 mg daily, with 1.8 mg daily as the maximum labeled dose [1].

Quick facts about Victoza doses for weight loss

Victoza is a daily subcutaneous injection, which means it is injected under the skin. Its active ingredient, liraglutide, acts like the GLP-1 hormone and helps improve blood sugar after meals by increasing insulin release when glucose is high, lowering glucagon, and slowing gastric emptying [1].

Is Victoza actually approved for weight loss?

Victoza is FDA-approved for type 2 diabetes, not weight loss. When it is used mainly for weight management, that is off-label use, even though liraglutide itself has been studied and approved for weight management under the Saxenda label at 3.0 mg once daily [1,2].

Victoza vs. Saxenda: the same drug at different doses

Victoza and Saxenda both contain liraglutide, a GLP-1 receptor agonist. The key difference is the FDA-labeled use and dose: Victoza is labeled up to 1.8 mg once daily for type 2 diabetes, while Saxenda is labeled at 3.0 mg once daily for chronic weight management [1,2].

What off-label use means for patients

Off-label use means a clinician prescribes an FDA-approved drug for a use, dose, or patient group that is not on that drug’s label. It can be medically appropriate, but it requires a clinical evaluation, risk review, and follow-up because the Victoza label does not define it as a weight-loss medicine [1,11].

What is the standard Victoza dosing schedule?

The Victoza FDA label gives a step-up schedule: 0.6 mg once daily for one week, then 1.2 mg once daily; if more glucose lowering is needed, the label allows an increase to 1.8 mg once daily [1]. These are label-based diabetes doses, not weight-loss instructions.

Week 1: starting dose (0.6 mg)

The Victoza label states that 0.6 mg once daily is used for the first week to reduce nausea and other stomach-related side effects during initiation [1]. Because this is a diabetes label dose, a clinician should explain how it applies if weight management is the reason for care.

Week 2: 1.2 mg maintenance

After one week, the Victoza label states that dosing is increased to 1.2 mg once daily [1]. People who also use insulin or a sulfonylurea may need closer monitoring because GLP-1 medicines can raise the risk of low blood sugar when combined with those drugs [1].

Week 3+: titration to 1.8 mg maximum

The Victoza label allows an increase to 1.8 mg once daily if additional glycemic control is needed after at least one week at 1.2 mg [1]. Dose changes should only be made under clinician supervision, especially if side effects appear or other diabetes medicines are being used [1].

How much weight can you expect to lose on each dose?

Liraglutide has been studied for weight loss, but the strongest weight-management evidence is for the Saxenda dose, not Victoza’s 1.8 mg maximum [2,7]. Individual results vary, and nausea, vomiting, diarrhea, constipation, and gallbladder problems were reported in liraglutide weight-management trials [2,7].

Evidence from liraglutide weight-loss trials

In a 20-week obesity trial, Astrup and colleagues studied liraglutide doses from 1.2 mg to 3.0 mg daily and found greater mean weight loss with higher liraglutide doses than placebo; nausea and vomiting were reported more often with liraglutide [6]. In the 56-week SCALE Obesity and Prediabetes trial, participants received liraglutide 3.0 mg daily plus lifestyle counseling, and the liraglutide group had greater average weight loss than placebo; gastrointestinal side effects and gallbladder-related events were also more common [7].

Why 3.0 mg (Saxenda) is the studied weight-loss dose

Saxenda’s FDA approval for chronic weight management is based on liraglutide 3.0 mg once daily in people meeting BMI and risk-factor criteria [2,7]. Victoza’s maximum labeled dose is lower at 1.8 mg once daily, so it should not be viewed as the same weight-management regimen as Saxenda [1,2].

When and how should you inject Victoza?

The Victoza label says it is injected once daily at any time of day, with or without food, under the skin of the abdomen, thigh, or upper arm [1]. The label also says the injection site should be changed, and Victoza should not be mixed with insulin [1].

Best time of day to take Victoza

The FDA label does not require a morning or evening injection; it states Victoza may be given once daily at any time, independent of meals [1]. A steady daily routine may make missed doses less likely, but the safest timing plan is the one agreed on with the prescribing clinician.

Injection sites and rotation

The label lists the abdomen, thigh, or upper arm as subcutaneous injection sites for Victoza [1]. Rotating sites can reduce local irritation, and injection-site reactions are listed among reported adverse events [1].

What to do if you miss a dose

The FDA label states that if more than 3 days have passed since the last Victoza dose, therapy should be restarted at 0.6 mg once daily to reduce gastrointestinal symptoms linked with reinitiation [1]. If a dose is missed, patients should follow the plan from their prescriber rather than doubling doses.

How does Victoza compare to other GLP-1 medications for weight loss?

Victoza is one GLP-1 option, but it is not the FDA-approved liraglutide product for weight loss. Other medicines, including Saxenda, Wegovy, Zepbound, and some compounded GLP-1 formulations from licensed 503A pharmacies, may come up during a clinician-led weight-management visit; the relevant FDA status and risks differ by product [2,4,5,10,12].

Victoza (liraglutide) vs. Saxenda (liraglutide 3.0 mg)

Victoza and Saxenda contain the same active drug, but their FDA labels are different. Saxenda is the liraglutide product studied and approved for weight management at 3.0 mg once daily, while Victoza is labeled for type 2 diabetes at up to 1.8 mg once daily [1,2].

Victoza vs. Ozempic (semaglutide)

Ozempic (semaglutide, a GLP-1 receptor agonist) is FDA-approved for type 2 diabetes, not weight loss, though semaglutide is approved for weight management under the Wegovy label [3,4]. In STEP 1, participants received once-weekly semaglutide 2.4 mg plus lifestyle intervention and had greater average weight loss than placebo; nausea, diarrhea, vomiting, and constipation were common [8].

Victoza vs. Wegovy and compounded semaglutide

Wegovy (semaglutide 2.4 mg, a GLP-1 receptor agonist) is FDA-approved for chronic weight management in eligible patients [4]. Compounded semaglutide is a separate category: it may be prepared by licensed 503A compounding pharmacies when legal conditions are met, but compounded products are not FDA-approved as finished drugs [12].

Victoza vs. Mounjaro / Zepbound (tirzepatide)

Mounjaro and Zepbound contain tirzepatide, a glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist; Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management in eligible adults [5,10]. In SURMOUNT-1, participants received once-weekly tirzepatide and had greater average weight loss than placebo; gastrointestinal adverse events were reported most often during dose escalation, and individual results vary [9].

What are the side effects at higher Victoza doses?

Victoza side effects are often stomach-related, and titration is used on the FDA label to reduce gastrointestinal symptoms during initiation [1]. Serious warnings include thyroid C-cell tumors, acute pancreatitis, gallbladder disease, kidney injury, and hypoglycemia when used with insulin or sulfonylureas [1].

Common GI side effects and how titration helps

The Victoza label lists nausea, diarrhea, vomiting, decreased appetite, indigestion, and constipation among common adverse reactions [1]. The starting 0.6 mg dose is described on the label as an initiation step to reduce gastrointestinal symptoms, not as the full therapeutic dose [1].

Serious warnings: thyroid C-cell tumors, pancreatitis

Victoza has a boxed warning for thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [1]. The label also warns that acute pancreatitis has been observed with liraglutide and that the drug should be discontinued if pancreatitis is suspected by a clinician [1].

How can you get a GLP-1 prescribed for weight loss?

A GLP-1 prescription for weight management starts with a clinical evaluation, not a dose request. Eligibility often depends on BMI, weight-related health conditions, medication history, contraindications, lab needs, and whether the medicine is FDA-approved for the intended use [2,4,10,11].

Clinical evaluation and eligibility

A clinician will usually review weight history, diabetes status, pregnancy plans, pancreatitis history, gallbladder disease, kidney function, current medicines, and any personal or family history of medullary thyroid carcinoma or MEN 2 [1,2,4,10]. This matters because GLP-1 and GIP/GLP-1 medicines have overlapping possible benefits and risks, but their FDA-approved uses are not the same [1,4,10].

Branded vs. compounded GLP-1 options

Branded GLP-1 medicines, such as Saxenda, Wegovy, and Zepbound, are FDA-approved finished drugs for specific uses on their labels [2,4,10]. Compounded GLP-1s, such as compounded semaglutide or compounded tirzepatide from a licensed 503A pharmacy, are not FDA-approved finished drugs, but may be considered when allowed under federal and state compounding rules [12].

Getting a prescription through Chia

Chia is one telehealth option where a licensed clinician can review eligibility for weight-management care, discuss branded and compounded GLP-1 options when appropriate, and decide whether a prescription is medically suitable. Any prescription should be based on the clinician’s judgment, FDA status, patient risk factors, and follow-up plan [11,12].

Frequently asked questions

Keep reading

GLP-1 Medications

GLP-1 Patches: Side Effects, Safety, and What They Actually Contain

Weight Loss

GLP-1 Peptides for Weight Loss: How They Work, Who Qualifies, and What to Expect

GLP-1 Medications

Victoza Dosing for Weight Loss: Titration, Max Dose, and What to Expect